var data={"title":"Human papillomavirus 9-valent vaccine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Human papillomavirus 9-valent vaccine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/762932?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=human-papillomavirus-9-valent-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Human papillomavirus 9-valent vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=human-papillomavirus-9-valent-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Human papillomavirus 9-valent vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639611\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gardasil 9</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48963098\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gardasil 9</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736137\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Inactivated (Viral)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736139\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=human-papillomavirus-9-valent-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Human papillomavirus 9-valent vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> If the HPV product previously administered is not known or not available, any available HPV vaccine product may be used to continue or complete the series for females for protection against HPV 16 and 18; the 9-valent HPV or 4-valent HPV may be used to continue or complete the series for males (CDC/ACIP [Petrosky 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;9 years and Adolescents &lt;15 years:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">2-dose series: IM: 0.5 mL per dose; administer the second dose at 6 to 12 months after initial dose. If the second dose is inadvertently administered earlier than 5 months after the first dose, then patient should be converted to a 3-dose series.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3-dose series: IM: 0.5 mL per dose; administer the second and third doses at 2 and 6 months after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;15 years: IM: 0.5 mL per dose for a total of 3 doses; administer the second and third doses at 2 and 6 months after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC/ACIP recommended immunization schedule: Routine vaccination at 11 to 12 years of age; may start as early as 9 years of age. In a 2-dose schedule, minimum interval between first and second doses is 5 months. In a 3-dose schedule, minimum interval between first and second doses is 4 weeks; the minimum interval between the second and third dose is 12 weeks; the minimum interval between first and third doses is 5 months (CDC/ACIP [Meites 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-immunocompromised patients and certain specified medical conditions: asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, central nervous system, anatomic barrier defects (eg, cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;9 years and Adolescents &lt;15 years: <i>2-dose series</i>: IM: 0.5 mL at 0, and 6 to 12 months. Administer first dose at age 11 to 12 years. For patients with any history of sexual abuse or assault, vaccination should be started at 9 years.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &ge;15 years: <i>3-dose series</i>: IM: 0.5 mL at 0, 1 to 2, and 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompromised patients, including those with conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, or immunosuppressive therapy: Children &ge;9 years and Adolescents: <i>3-dose series</i>: IM: 0.5 mL at 0, 1 to 2, and 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catch-up immunization:</b> CDC/ACIP recommendations (Meites 2016): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number. Children &ge;9 years and Adolescents: IM: 0.5 mL per dose for a total of 2 to 3 doses (See CDC/ACIP recommendations above for 2-dose vs 3-dose schedule criteria):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose given on the elected date.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose given at least 4 weeks after the first dose (for a 3-dose schedule) or 5 months after the first dose (for a 2-dose schedule).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third dose (for a 3-dose schedule) given at least 12 weeks after the second dose and at least 5 months after the first dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CDC/ACIP recommended immunization schedule: Vaccination recommended in females and transgender persons &le;26 years or males &le;21 years if not previously vaccinated or completed the series (typically administer first dose at age 11 to 12 years). Vaccination for males 22 through 26 years of age is recommended if immunocompromised (including HIV) and for men who have sex with men and may be considered for any other male in this age group. Administer the second and third doses at 1 to 2 months and 6 months after the first dose. Second and third doses may be given after age 26 years to complete a previously initiated series (CDC/ACIP [Markowitz 2014]; CDC/ACIP [Meites 2016].</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Have not received any doses</i>: 3-dose series: IM: 0.5 mL at 0, 1 to 2, and 6 months. There should be a 4-week minimum interval between the first and second dose; a 12-week minimum interval between the second and third dose; a 5-month minimum interval between the first and third dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Partially vaccinated, first dose before 15 years of age</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If 2 doses administered at least 5 months apart: no more doses needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If only a single dose or if doses &lt;5 months apart: IM: Administer one additional 0.5 mL dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Partially vaccinated, first dose at 15 years of age or later</i>: Complete 3-dose series: IM: There should be a 4-week minimum interval between the first and second dose; a 12-week minimum interval between the second and third dose; a 5-month minimum interval between the first and third dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Adults &le;26 years: IM: 0.5 mL per dose for a total of 3 doses; administer the second and third doses at 2 and 6 months after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639612\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gardasil 9:  (0.5 mL) [contains polysorbate 80, yeast extract]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Prefilled Syringe, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gardasil 9:  (0.5 mL) [contains polysorbate 80, yeast extract]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639610\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46561285\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">In the US, the appropriate CDC-approved  Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv-gardasil-9.html&amp;token=W2kSAaOjZU9MrMfHTzJjF6NZqGSoVD7pMAn8fa6fl4H2eneL34e9lv8f+ihizQSjDrWkISN625XMMACQdiYZSQpjG1R8MtCJfLTzLcmf5O0=&amp;TOPIC_ID=101845\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv-gardasil-9.html</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736141\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Shake suspension well before use. Do not use if discolored or if contains particulate matter, or if syringe is cracked. Inject the entire dose IM into the deltoid region of the upper arm or higher anterolateral thigh area. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26869401\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze. Protect from light.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer as soon as possible after being removed from refrigeration. HPV 9-valent vaccine can be administered provided total (cumulative multiple excursion) time out of refrigeration (at temperatures between 8&deg;C and 25&deg;C) does not exceed 72 hours. Cumulative multiple excursions between 0&deg;C and 2&deg;C are also permitted as long as the total time between 0&deg;C and 2&deg;C does not exceed 72 hours. These are not, however, recommendations for storage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736138\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of the following: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; genital warts caused by HPV types 6 and 11; cervical adenocarcinoma in situ; and vulvar, vaginal, cervical, or anal intraepithelial neoplasia caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (FDA approved in females ages 9 to 26 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of the following: Genital warts caused by HPV types 6 and 11; anal cancer caused by HPV types 16, 18, 31, 33, 45, 52, and 58; and anal intraepithelial neoplasia caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (FDA approved in males ages 9 to 26 years)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females and males 11 to 12 years of age; for patients with any history of sexual abuse or assault, vaccination should be started at 9 years of age. Catch-up vaccination is recommended for females and transgender persons 13 to 26 years of age and males 13 to 21 years of age. Vaccination for males 22 through 26 years of age is recommended if immunocompromised (including HIV) and for men who have sex with men and may be considered for any other male in this age group (CDC/ACIP [Meites 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26619129\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Papillomavirus vaccine 9-valent (Gardasil 9) may be confused with Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine, 9vHPV is the correct abbreviation) may be confused with IPV (inactivated poliovirus vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine, 9vHPV is the correct abbreviation) may be confused with HBV (previously used for hepatitis B vaccine; HepB is correct abbreviation)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">HPV (human papilloma virus vaccine, 9vHPV is the correct abbreviation) may be confused with Hib (<i>Haemophilus</i> b conjugate vaccine)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27368406\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">To report <b>suspected adverse reactions</b>, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at (877) 888-4231 or VAERS at (800) 822-7967 or <a target=\"_blank\" href=\"http://www.vaers.hhs.gov&amp;token=6g5UpsuthFnSGzoQK/MSszhTvjA3oWEYSHIRzziY8F+vALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=101845\" target=\"_blank\">http://www.vaers.hhs.gov</a>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Central nervous system: Dizziness, fatigue, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Gastrointestinal: Diarrhea, nausea, upper abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Immunologic: Autoimmune disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Local: Bleeding at injection site, bruising at injection site, erythema at injection site (erythema increases with successive doses), hematoma at injection site, induration at injection site, itching at injection site, injection site nodule, injection site reaction, pain at injection site, swelling at injection site (swelling increased with successive doses and/or concomitant vaccines)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Neuromuscular &amp; skeletal: Myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Respiratory: Oropharyngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Rare but important or life-threatening: Anaphylactoid reaction, hypersomnia, postural orthostatic tachycardia, pulmonary embolism, status asthmaticus, tonsillitis, upper respiratory tract infection, warm sensation at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26619132\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of this vaccine or human papillomavirus vaccine (recombinant) for types 6, 11, 16, 18</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26869399\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human papillomavirus (HPV) infection: There is no evidence that individuals already infected with HPV will be protected; those already infected with 1 or more HPV types were protected from disease caused by the remaining HPV types. Not for the treatment of active disease; will not protect against diseases not caused by HPV vaccine types not included in the vaccine. Does not eliminate the necessity for recommended cervical or anal cancer screenings.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i> Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Previously vaccinated with Gardasil (quadrivalent): Safety and immunogenicity of Gardasil 9 were assessed in individuals who previously completed a 3-dose vaccination series with Gardasil (quadrivalent). Studies using a mixed regimen of HPV vaccines to assess interchangeability were not performed. Per the ACIP, if the provider does not have available or does not know the HPV product used previously, any gender appropriate product can be used to complete the series (CDC/ACIP [Petrosky 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Yeast: Product may contain yeast.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Maximum efficacy: The entire series should be completed for maximum efficacy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639798\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639795\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101845&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26869396\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were not observed in animal reproduction studies. In clinical trials, women who were found to be pregnant before the completion of the 3-dose regimen were instructed to defer any remaining dose until pregnancy resolution. In pregnancies detected within 30 days of vaccination, no cases of congenital abnormalities were noted. Pregnancies with onset beyond 30 days of vaccination had a rate of congenital anomalies consistent with the general population. Administration of the vaccine in pregnancy is not recommended. Until additional information is available, the vaccine series (or completion of the series) should be delayed until pregnancy is completed. Pregnancy testing is not required prior to administration of the vaccine (CDC/ACIP [Petrosky 2015]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A registry has been established for women exposed to the Gardasil 9 HPV vaccine during pregnancy (1-800-986-8999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736142\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Screening for HPV is not required prior to vaccination. Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. Continue recommended anal cancer screening.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females: Gynecologic screening exam, papillomavirus test; screening for cervical cancer should continue per current guidelines following vaccination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26869404\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Contains inactive human papillomavirus (HPV) proteins (types 6 L1,11 L1, 16 L1, 18 L1, 31 L1, 33 L1, 45 L1, 52 L1, and 58 L1) which produce neutralizing antibodies to prevent cervical, vulvar, vaginal, and anal  cancers, cervical adenocarcinoma, cervical, vaginal, vulvar, and anal neoplasia, and genital warts caused by HPV. Efficacy of HPV 9-valent vaccine against anogenital diseases related to the vaccine HPV types in humans is thought to be mediated by humoral immune responses induced by the vaccine, although the exact mechanism of protection is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27736143\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Ideally, administration of vaccine should occur prior to potential HPV exposure. Benefits of vaccine decrease once infected with &ge;1 of the HPV vaccine types, although patients are protected from precancerous cervical lesions and external genital lesions caused by other HPV vaccine types.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Comparison of HPV vaccines: Cervarix, Gardasil, and Gardasil 9 are all vaccines formulated to protect against infection with the human papillomavirus. All are inactive vaccines which contain proteins HPV 16 L1 and HPV 18 L1, the cause of &gt;70% of invasive cervical cancer. The vaccines differ in that Gardasil also contains HPV 6 L1 and HPV 11 L1 proteins which protect against 75% to 90% of genital warts. Gardasil 9 adds HPV 31 L1, HPV 33 L1, HPV 45 L1, HPV 52 L1, and HPV 58 L1. The vaccines also differ in their preparation and adjuvants used. The viral proteins in Cervarix are prepared using <i>Trichoplusia ni</i> (insect cells) which are adsorbed on to an aluminum salt which is also combined with a monophosphoryl lipid. The viral proteins in Gardasil and Gardasil 9 are prepared using <i>Saccharomyces cerevisiae</i> (baker's yeast) which are then adsorbed to an aluminum salt. Results from a short-term study (measurements obtained 1 month following the third vaccination in the series) have shown that the immune response to HPV 16 and HPV 18 may be greater with Cervarix than with Gardasil; although the clinical significance of this difference is not known, local adverse events may occur more frequently with Cervarix. Both vaccines were effective and results from long-term studies are pending (Einstein 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48851701\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Gardasil 9 (AT, AU, CZ, DE, DK, EE, HK, HR, KR, LT, LV, MY, NZ, PH, PL, PT, RO, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einstein MH, Baron M, Levin MJ, et al; HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. <i>Hum Vaccin</i>. 2009;5(10):705-719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/19684472/pubmed\" target=\"_blank\" id=\"19684472\">19684472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardasil 9 (human papilloma virus 9-valent vaccine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2014;63(RR-05):1-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/25167164/pubmed\" target=\"_blank\" id=\"25167164\">25167164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(49):1405-1408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/27977643/pubmed\" target=\"_blank\" id=\"27977643\">27977643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):300-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/25811679 /pubmed\" target=\"_blank\" id=\"25811679 \">25811679 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/24311479 /pubmed\" target=\"_blank\" id=\"24311479 \">24311479 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/human-papillomavirus-9-valent-vaccine-pediatric-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101845 Version 36.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26639611\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F48963098\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F27736137\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F27736139\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26639612\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F26639610\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F46561285\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27736141\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F26869401\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F27736138\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26619129\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27368406\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26619132\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26869399\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26639798\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F26639795\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26869396\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27736142\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26869404\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F27736143\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F48851701\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/101845|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=human-papillomavirus-9-valent-vaccine-drug-information\" class=\"drug drug_general\">Human papillomavirus 9-valent vaccine: Drug information</a></li><li><a href=\"topic.htm?path=human-papillomavirus-9-valent-vaccine-patient-drug-information\" class=\"drug drug_patient\">Human papillomavirus 9-valent vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}